Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week

R. Ferreiro-Iglesias, A. Jardi, A. Quiroga, I. Baston, J. Gonzalez, J. M. Giraldez, I. Zarra, M. J. Lamas, J. E. Dominguez-Munoz, M. Barreiro-de Acosta

Research output: Contribution to journalMeeting Abstract

Original languageEnglish
Pages (from-to)S390-S391
JournalJournal of Crohn's and Colitis
Volume13
Publication statusPublished - Mar 2019

Cite this

Ferreiro-Iglesias, R., Jardi, A., Quiroga, A., Baston, I., Gonzalez, J., Giraldez, J. M., Zarra, I., Lamas, M. J., Dominguez-Munoz, J. E., & Barreiro-de Acosta, M. (2019). Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week. Journal of Crohn's and Colitis, 13, S390-S391.